{"disease":{"id":"telangiectasias","name":"telangiectasias"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06962813","title":"Transdermal Radiofrequency V ERASER Versus Polidocanol Sclerotherapy for Reticular Veins and Telangiectasias","phase":"NA","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Science Valley Research Institute","has_results":false},{"nct_id":"NCT02761174","title":"Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Merete Haedersdal","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}